SCHEMBL1664803

SCHEMBL1664803

Cc1ccc(-c2cn3cc(Cl)ccc3n2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.83
NPC1 O15118 10/20 0.83
ALDH1A1 P00352 10/20 0.74
SMN1; SMN2 Q16637 8/20 0.74
KDM4E B2RXH2 7/20 0.74
PAX8 Q06710 2/20 0.74
KMT2A Q03164 2/20 0.74
MEN1 O00255 1/20 0.74
MITF O75030 1/20 0.74
KDM5A P29375 1/20 0.74
KDM5C P41229 1/20 0.74
APP P05067 3/20 0.72
ALDH1A3 P47895 3/20 0.64
SLC2A1 P11166 1/20 0.64
MAPT P10636 4/20 0.61
HPGD P15428 2/20 0.61
TSHR P16473 2/20 0.61
HSD17B10 Q99714 2/20 0.61
PKM P14618 2/20 0.59
NFKB1 P19838 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691409 0.91 RAB9A (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1691254 0.90 NPC1 (0.80) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL396368 0.85 NPC1 (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL5775919 0.85 RAB9A (0.81) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13217820 0.85 RAB9A (0.81) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13325716 0.85 RAB9A (0.81) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL2404662 0.84 RAB9A (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13198279 0.84 RAB9A (0.73) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13217828 0.84 ALDH1A3 (0.75) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13325772 0.84 ALDH1A3 (0.87) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
CN-112538087-B Synthesis method of imidazopyridine compound 温州大学新材料与产业技术研究院 2021-10-15 CN disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
EP-1891042-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA SA (BE) 2013-10-02 EP disclosed
EP-1891042-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA SA (BE) 2013-10-02 EP disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP disclosed
US-20070120111-A1 Organic thin film transistor IDEMITSU KOSAN CO., LTD. (JP) 2007-05-31 US disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 RAB9A 547/4885NPC1 416/4885ALDH1A1 560/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 RAB9A 778/4885NPC1 404/4885ALDH1A1 447/4885
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A RAB9A 3350/4885NPC1 4209/4885ALDH1A1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.